These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 33767588)

  • 1. miR-26b enhances the sensitivity of hepatocellular carcinoma to Doxorubicin via USP9X-dependent degradation of p53 and regulation of autophagy.
    Chen E; Li E; Liu H; Zhou Y; Wen L; Wang J; Wang Y; Ye L; Liang T
    Int J Biol Sci; 2021; 17(3):781-795. PubMed ID: 33767588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
    Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
    Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.
    Jin F; Wang Y; Li M; Zhu Y; Liang H; Wang C; Wang F; Zhang CY; Zen K; Li L
    Cell Death Dis; 2017 Jan; 8(1):e2540. PubMed ID: 28079894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA-26b inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting USP9X.
    Shen G; Lin Y; Yang X; Zhang J; Xu Z; Jia H
    BMC Cancer; 2014 Jun; 14():393. PubMed ID: 24890815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-34a overexpression enhances the inhibitory effect of doxorubicin on HepG2 cells.
    Zheng SZ; Sun P; Wang JP; Liu Y; Gong W; Liu J
    World J Gastroenterol; 2019 Jun; 25(22):2752-2762. PubMed ID: 31235998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.
    Zhao N; Wang R; Zhou L; Zhu Y; Gong J; Zhuang SM
    Mol Cancer; 2014 Feb; 13():35. PubMed ID: 24565101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53-dependent upregulation of miR-16-2 by sanguinarine induces cell cycle arrest and apoptosis in hepatocellular carcinoma.
    Zhang B; Wang X; Deng J; Zheng H; Liu W; Chen S; Tian J; Wang F
    Cancer Lett; 2019 Sep; 459():50-58. PubMed ID: 31163195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
    Xu L; Beckebaum S; Iacob S; Wu G; Kaiser GM; Radtke A; Liu C; Kabar I; Schmidt HH; Zhang X; Lu M; Cicinnati VR
    J Hepatol; 2014 Mar; 60(3):590-8. PubMed ID: 24211739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H; Yu Z; Liu Y; Yuan W; Yang T; You J; He X; Lee RJ; Li L; Xu C
    Int J Nanomedicine; 2017; 12():5271-5287. PubMed ID: 28769563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells.
    Zhou Y; Chen E; Tang Y; Mao J; Shen J; Zheng X; Xie S; Zhang S; Wu Y; Liu H; Zhi X; Ma T; Ni H; Chen J; Chai K; Chen W
    Cell Death Dis; 2019 Nov; 10(11):843. PubMed ID: 31695022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma.
    Wang Y; Sun B; Zhao X; Zhao N; Sun R; Zhu D; Zhang Y; Li Y; Gu Q; Dong X; Wang M; An J
    Oncotarget; 2016 Apr; 7(17):24383-401. PubMed ID: 27027434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.
    Fornari F; Milazzo M; Galassi M; Callegari E; Veronese A; Miyaaki H; Sabbioni S; Mantovani V; Marasco E; Chieco P; Negrini M; Bolondi L; Gramantieri L
    Mol Cancer Res; 2014 Feb; 12(2):203-16. PubMed ID: 24324033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
    Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
    J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-375 attenuates sorafenib resistance of hepatocellular carcinoma cells by inhibiting cell autophagy.
    Wang D; Yang J
    Acta Biochim Pol; 2023 Apr; 70(2):239-246. PubMed ID: 37068178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.
    Xu F; Liao JZ; Xiang GY; Zhao PX; Ye F; Zhao Q; He XX
    Cancer Med; 2017 Mar; 6(3):651-661. PubMed ID: 28135055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.
    Tu C; Chen W; Wang S; Tan W; Guo J; Shao C; Wang W
    J Cell Mol Med; 2019 Nov; 23(11):7190-7199. PubMed ID: 30801960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling.
    Tang G; Zhao H; Xie Z; Wei S; Chen G
    Bioengineered; 2022 Mar; 13(3):7829-7846. PubMed ID: 35291921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-372-3p Predicts Response of TACE Patients Treated with Doxorubicin and Enhances Chemosensitivity in Hepatocellular Carcinoma.
    Soliman MH; Ragheb MA; Elzayat EM; Mohamed MS; El-Ekiaby N; Abdelaziz AI; Abdel-Wahab AA
    Anticancer Agents Med Chem; 2021; 21(2):246-253. PubMed ID: 32416702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.